Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Lacrimal Apparatus Diseases 1Lacerations 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endophthalmitis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fluorometholone × Clear all
NCT00824811 2012-08-02

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

M.D. Anderson Cancer Center

Phase 2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Lacrimal Apparatus Diseases, Lung Neoplasms, Endophthalmitis, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Lacerations, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡